wockair.co.uk valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-Agent: * Allow: /wp-content/uploads/ Disallow: /wp-content/plugins/ Disallow: /wp-admin/ Disallow: /readme.html Disallow: | ||
Meta Tags
| Title | Introducing WockAIR® - |
| Description | Introducing WockAIR® - A dry powder inhaler for the treatment of Asthma and |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 153.92.7.42 |
| Location | Germany |
Related Websites
| Site | Rank |
More to Explore
wockair.co.uk Valuation
|
US$265,518
Last updated: 2023-05-16 12:10:46
wockair.co.uk has Semrush global rank of 39,862,853. wockair.co.uk has an estimated worth of US$ 265,518, based on its estimated Ads revenue. wockair.co.uk receives approximately 30,637 unique visitors each day. Its web server is located in Germany, with IP address 153.92.7.42. According to SiteAdvisor, wockair.co.uk is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$265,518 |
| Daily Ads Revenue | US$246 |
| Monthly Ads Revenue | US$7,353 |
| Yearly Ads Revenue | US$88,234 |
| Daily Unique Visitors | 2,043 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| wockair.co.uk. | A | 7199 | IP: 153.92.7.42 |
| wockair.co.uk. | NS | 3600 | NS Record: ns63.domaincontrol.com. |
| wockair.co.uk. | NS | 3600 | NS Record: ns64.domaincontrol.com. |
| wockair.co.uk. | MX | 21600 | MX Record: 10 mail.wockair.co.uk. |
HtmlToTextCheckTime:2023-05-16 12:10:46
| PRESCRIBING INFORMATION – INTENDED FOR UK HEALTHCARE PROFESSIONALS INTENDED FOR UK PATIENTS WockAIR® Place in Therapy Dosing & Administration WockAIR® Device Patient experience Safety MART Patient Information Contact Us Reporting a Side Effect Menu Menu INTRODUCING WOCKAIR ® (budesonide/formoterol fumarate dihydrate, inhalation powder) A dry powder inhaler for the treatment of Asthma and COPD¹ Bioequivalent to Symbicort ® Turbohaler ® * with lower acquisition costs ¹˒²˒³˒⁴ (Based on 80-125% bioequivalence limits for AUC, Cmax, and standard flow parameters) Preferred controller and reliever for adults and adolescents over 12 years with asthma in GINA guidelines⁵ Patient friendly device with multiple feedback mechanisms, with a lower carbon footprint than pMDIs (in line with NHS carbon reduction strategy)⁶˒⁷ Learn more ASTHMA WockAIR ® is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and |
HTTP Headers
HTTP/1.1 403 Forbidden Content-Type: text/html Cache-Control: no-cache, no-store, must-revalidate Pragma: no-cache Expires: 0 Server: BitNinja Captcha Server Date: Tue, 25 Jan 2022 12:04:01 GMT Content-Length: 13714 Connection: close |